In summary, we found that ERAP2, a previously unreported biomarker, predicts sensitivity to gemcitabine in patients with pancreatic cancer, possibly acting in part through the PI3K/AKT/mTOR signaling pathway. This evidence concerns the gene AKT1 and familial pancreatic carcinoma.